The Maxwell Finland lecture: For the duration - Rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 491-496

  Rice, Louis B ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; ISONIAZID; LEVOFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; COLONY FORMING UNIT; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; ENDOCARDITIS; ENTEROCOCCACEAE; ENTEROCOCCUS FAECIUM; HEALTH CARE SYSTEM; HUMAN; INFECTION SENSITIVITY; LOBAR PNEUMONIA; MENINGITIS; MYCOBACTERIUM TUBERCULOSIS; PHARYNGITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEXUALLY TRANSMITTED DISEASE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION; DRUG EFFECT; MICROBIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 38849164375     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526535     Document Type: Conference Paper

References (32)

1. Woodford N, Ellington MJ. The emergence of antibiotic resistance by mutation. Clin Microbiol Infect 2007; 13:5-18.
2. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104:9451-6.
3. Holden MT, Feil EJ, Lindsay JA, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci USA 2004; 101:9786-91.
4. Paulsen IT, Banerjei L, Myers GS, et al. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 2003; 299:2071-4.
5. Leavis HL, Willems RJ, vanWamel WJ, Schuren FH, Caspers MP, Bonten MJ. Insertion sequence-driven diversification creates a globally dispersed emerging multiresistant subspecies of E. faecium. PLoS Pathog 2007; 3:e7.
6. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
7. Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001; 39:2072-8.
8. Fournier PE, Vallenet D, Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2:e7.
9. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 2000; 181:1830-3.
10. Michea-Hamzehpour M, Auckenthaler R, Regamey P, Pechere JC. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31:1803-8.
11. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 2006; 43(Suppl 2):S82-8.
12. Arason VA, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. The role of antimicrobial use in the epidemiology of resistant pneumococci: a 10-year follow up. Microb Drug Resist 2006; 12:169-76.
13. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:905-9.
14. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
15. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499-539.
16. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-406.
17. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643-54.
18. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267-84.
19. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 2006; 117:212S-38S.
20. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
21. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
22. Keefer CS, Blake FG, Marshall EK, Lockwood JS, Wood BW. Penicillin in the treatment of infections: report of 500 cases. JAMA 1943; 122:1217-24.
23. Dawson ML, Hobby GL. The clinical use of penicillin: observations in one hundred cases. JAMA 1944; 124:611-22.
24. Tillett WS, Cambier MJ, McCormack JE. Treatment of lobar pneumonia and pneumococcal empyema. Bull NY Acad Med 1944; 20:142-78.
25. Meads M, Harris W, Finland M. Treatment of pneumococcal pneumonia with penicillin. N Engl J Med 1945; 232:749-55.
26. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double blind study. BMJ 2006; 332:1355.
27. Stewart WH. A mandate for state action. In: Proceedings of the Association of State and Territorial Health Officers. 1967. Available at: http://pages.pomona.edu/~nvh04747/Bio189L/intro.html. Accessed 10 January 2008.
28. Humana. Top 50 drugs prescribed. 2007. Available at: http://apps.humana.com/marketing/documents.asp?filep926328. Accessed 29 October 2007.
29. McFadyen RE. The FDA's regulation and control of antibiotics in the 1950s: the Henry Welch scandal, Felix Marti-Ibanez, and Charles Pfizer & Co. Bull Hist Med 1979; 53:159-69.
30. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98.
31. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11.
32. Stop Hospital Infections.org. Summary of state activity. Available at: http://www.consumersunion.org/campaigns/learn_more_background/003544indiv.html. Accessed 29 October 2007.